Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Nanoviricides Inc
(NY:
NNVC
)
1.430
+0.070 (+5.15%)
Official Closing Price
Updated: 6:30 PM EDT, Oct 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Nanoviricides Inc
< Previous
1
2
3
4
5
6
Next >
12 Health Care Stocks Moving In Tuesday's After-Market Session
June 04, 2024
Via
Benzinga
The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect
June 04, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Monday's After-Market Session
June 03, 2024
Via
Benzinga
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results
May 29, 2024
Via
AB Newswire
A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More
May 29, 2024
Via
ACCESSWIRE
Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure
May 20, 2024
Via
ACCESSWIRE
NanoViricides Has Filed its Quarterly Report
May 15, 2024
Via
ACCESSWIRE
A Novel Broad-Spectrum Antiviral with Activity Against RSV
May 14, 2024
Via
ACCESSWIRE
NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.
May 23, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Intraday Session
May 16, 2024
Via
Benzinga
NNVC Stock Earnings: Nanoviricides Beats EPS for Q3 2024
May 15, 2024
NNVC stock results show that Nanoviricides beat analyst estimates for earnings per share the third quarter of 2024.
Via
InvestorPlace
NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City
May 10, 2024
Via
ACCESSWIRE
A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox
May 08, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Monday's Intraday Session
May 06, 2024
Via
Benzinga
A Novel Broad-Spectrum Antiviral with Activity Against Influenza A
May 06, 2024
Via
ACCESSWIRE
3 Nanotech Stocks With the Potential to Make You an Overnight Millionaire
May 02, 2024
Discover three nanotech stocks poised for explosive growth in a booming market. Explore their potential for massive returns.
Via
InvestorPlace
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
April 30, 2024
Via
ACCESSWIRE
NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon
February 15, 2024
Via
ACCESSWIRE
Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics
February 01, 2024
Via
ACCESSWIRE
A New COVID-19 Variant Is Rapidly Spreading Around The Globe, Other Pandemic Threats Exist – What Are The Choices For Treatment?
January 31, 2024
Colds, flu and RSV aren't the only viral illnesses people have to worry about this winter. A new variant of COVID-19 is rapidly spreading, reminding the world of just how dangerous this virus is.
Via
Benzinga
Exposures
COVID-19
Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found
January 29, 2024
Via
ACCESSWIRE
NanoViricides, Inc. (NNVC) To Unveil Cutting-Edge Antiviral Breakthroughs At Biotech Showcase™ 2024
January 08, 2024
NanoViricides, Inc. (NYSE American: NNVC) recently announced that it is presenting at Biotech Showcase™ 2024. Event Information: Event NanoViricides Presentation at the Biotech Showcase, San Fransisco
Via
Benzinga
NanoViricides to Present at the Biotech Showcase in San Fransisco
January 04, 2024
Via
ACCESSWIRE
Is This Ticker That InvestorsObserver Expects To Soar By More Than 350% Next Year On Your Watchlist?
December 01, 2023
--News Direct--
Via
News Direct
Topics
Death
Exposures
COVID-19
Death
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
November 28, 2023
Via
ACCESSWIRE
NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
November 15, 2023
Via
ACCESSWIRE
Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
November 14, 2023
Via
ACCESSWIRE
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
October 16, 2023
Via
ACCESSWIRE
NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
October 12, 2023
Via
ACCESSWIRE
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
October 02, 2023
Read the latest report on NanoViricides here
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.